Aelis Farma SA (AELIS.PA)
EUR 2.18
(2.83%)
EUR 2.18
(2.83%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -6.34 Million EUR | -14.02% |
| 2022 | -16.22 Million EUR | -353.98% |
| 2021 | 844 Thousand EUR | 217.27% |
| 2020 | -3.56 Million EUR | 4.69% |
| 2019 | -4.51 Million EUR | -14.57% |
| 2018 | -3.47 Million EUR | -30.38% |
| 2017 | -1.98 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.76 Million EUR | 0.0% |
| 2024 Q1 | -1.76 Million EUR | 11.92% |
| 2023 Q2 | -4.35 Million EUR | -264.95% |
| 2023 FY | - EUR | -14.02% |
| 2023 Q3 | -1.98 Million EUR | 54.48% |
| 2023 Q1 | -1.19 Million EUR | 80.58% |
| 2023 Q4 | -2 Million EUR | -1.39% |
| 2022 Q2 | -6.86 Million EUR | -198.13% |
| 2022 Q4 | -6.14 Million EUR | -217.39% |
| 2022 FY | - EUR | -353.98% |
| 2022 Q1 | -2.3 Million EUR | -120.95% |
| 2022 Q3 | -1.93 Million EUR | 71.84% |
| 2021 Q2 | 2.33 Million EUR | 0.0% |
| 2021 Q1 | 2.33 Million EUR | 398.88% |
| 2021 FY | - EUR | 217.27% |
| 2021 Q4 | -1.04 Million EUR | -0.14% |
| 2021 Q3 | -1.04 Million EUR | -144.68% |
| 2020 Q2 | -630 Thousand EUR | 0.0% |
| 2020 Q1 | -630 Thousand EUR | 0.0% |
| 2020 FY | - EUR | 4.69% |
| 2020 Q4 | -779.75 Thousand EUR | -0.25% |
| 2020 Q3 | -777.83 Thousand EUR | -23.47% |
| 2019 FY | - EUR | -14.57% |
| 2018 FY | - EUR | -30.38% |
| 2017 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -92.918% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 95.235% |
| Adocia SA | -22.73 Million EUR | 72.079% |
| Biophytis S.A. | -13.8 Million EUR | 54.021% |
| Advicenne S.A. | -6.24 Million EUR | -1.65% |
| genOway Société anonyme | 6.35 Million EUR | 199.941% |
| IntegraGen SA | -52.5 Thousand EUR | -11988.833% |
| Medesis Pharma S.A. | -3.84 Million EUR | -65.077% |
| Neovacs S.A. | -8.44 Million EUR | 24.884% |
| NFL Biosciences SA | -4.04 Million EUR | -56.743% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 8850.862% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -120.882% |
| Sensorion SA | -22.31 Million EUR | 71.556% |
| Theranexus Société Anonyme | -7.38 Million EUR | 14.081% |
| TME Pharma N.V. | -5.07 Million EUR | -25.138% |
| Valbiotis SA | -6.95 Million EUR | 8.742% |
| TheraVet SA | -517.33 Thousand EUR | -1126.862% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 66.446% |
| argenx SE | -199.5 Million EUR | 96.819% |
| BioSenic S.A. | -6.79 Million EUR | 6.607% |
| Celyad Oncology SA | -7.76 Million EUR | 18.24% |
| DBV Technologies S.A. | -79.53 Million EUR | 92.019% |
| Galapagos NV | 51.03 Million EUR | 112.436% |
| Genfit S.A. | -28.05 Million EUR | 77.373% |
| GeNeuro SA | -14.31 Million EUR | 55.67% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 57.63% |
| Innate Pharma S.A. | -7.57 Million EUR | 16.244% |
| Inventiva S.A. | -101.84 Million EUR | 93.768% |
| MaaT Pharma SA | -19.74 Million EUR | 67.847% |
| MedinCell S.A. | -20.04 Million EUR | 68.338% |
| Nanobiotix S.A. | -34.01 Million EUR | 81.343% |
| Onward Medical N.V. | -35.23 Million EUR | 81.986% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -43.165% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 72.72% |
| Oxurion NV | -16.72 Million EUR | 62.06% |
| Pharming Group N.V. | 4.98 Million EUR | 227.425% |
| Poxel S.A. | -12.17 Million EUR | 47.886% |
| GenSight Biologics S.A. | -21.73 Million EUR | 70.792% |
| Transgene SA | -27.02 Million EUR | 76.513% |
| Financière de Tubize SA | 184.57 Thousand EUR | 3538.785% |
| UCB SA | 1.26 Billion EUR | 100.5% |
| Valneva SE | -64.51 Million EUR | 90.162% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 77.614% |